The Effects of Psilocybin on Social Connectedness

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT07693153
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Grief
  • Loneliness

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Psilocybin — DRUG
    25 mg
  • Placebo — DRUG
    Placebo capsule

Study Details

The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.

Key Dates

First listed
Jul 9, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Dec 15, 2031
Completion
Dec 15, 2031

Study Design

Enrollment
51 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Placebo
    Capsule
  • Active Comparator: Psilocybin
    25 mg

Primary Outcome Measure

Loneliness and social connectedness [ Time Frame: Baseline (Day -1) and Day +7, Day +30 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Connecticut Mental Health CenterNew HavenConnecticut06519
Anahita Bassir Nia, MD
[email protected]
Anahita Bassir Nia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Connecticut Mental Health Center· New Haven, CT

Related Studies